BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 17906340)

  • 1. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study.
    Ellis SG; Kandzari D; Kereiakes DJ; Pichard A; Huber K; Resnic F; Yakubov S; Callahan K; Borgman M; Cohen SA
    J Invasive Cardiol; 2007 Oct; 19(10):404-9. PubMed ID: 17906340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
    Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
    Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts.
    Gioia G; Benassi A; Mohendra R; Chowdhury K; Masood I; Matthai W
    Catheter Cardiovasc Interv; 2008 Jul; 72(1):13-20. PubMed ID: 18561143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease.
    Minutello RM; Bhagan S; Sharma A; Slotwiner AJ; Feldman DN; Cuomo LJ; Wong SC
    J Interv Cardiol; 2007 Dec; 20(6):458-65. PubMed ID: 18042050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease.
    Ramana RK; Ronan A; Cohoon K; Homan D; Sutherland J; Steen L; Liu J; Loeb H; Lewis BE
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):886-93. PubMed ID: 18412238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry).
    Lee MS; Hu PP; Aragon J; Shah AP; Oyama J; Dhoot J; Iqbal Z; Jones N; Penny W; Tobis J; Mahmud E; French W
    Am J Cardiol; 2010 Aug; 106(3):337-41. PubMed ID: 20643242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions.
    Price MJ; Sawhney N; Kao JA; Madrid A; Schatz RA; Teirstein PS
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):208-11. PubMed ID: 15880798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
    Jeger RV; Schneiter S; Kaiser C; Bonetti PO; Brunner-La Rocca H; Handke M; Osswald S; Buser PT; Pfisterer ME;
    Cardiology; 2009; 112(1):49-55. PubMed ID: 18580059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial.
    Moses JW; Nikolsky E; Mehran R; Cambier PA; Bachinsky WB; Leya F; Kuntz RE; Popma JJ; Schleckser P; Wang H; Cohen SA; Leon MB;
    Am J Cardiol; 2006 Dec; 98(11):1455-60. PubMed ID: 17126649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry).
    Vignali L; Saia F; Manari A; Santarelli A; Rubboli A; Varani E; Piovaccari G; Menozzi A; Percoco G; Benassi A; Rusticali G; Marzaroli P; Guastaroba P; Grilli R; Maresta A; Marzocchi A
    Am J Cardiol; 2008 Apr; 101(7):947-52. PubMed ID: 18359313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results].
    Lozano I; García-Camarero T; Carrillo P; Baz JA; de la Torre JM; López-Palop R; Pinar E; Salvatella N; Avanzas P; Valdés M
    Rev Esp Cardiol; 2009 Jan; 62(1):39-47. PubMed ID: 19150013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of drug-eluting stents versus bare-metal stents in saphenous vein grafts lesions: a meta-analysis.
    Sanchez-Recalde A; Jiménez Valero S; Moreno R; Barreales L; Lozano I; Galeote G; Martín Reyes R; Calvo L; Lopez-Sendon JL
    EuroIntervention; 2010 May; 6(1):149-60. PubMed ID: 20542811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial.
    Pache J; Dibra A; Mehilli J; Dirschinger J; Schömig A; Kastrati A
    Eur Heart J; 2005 Jul; 26(13):1262-8. PubMed ID: 15737962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry).
    Zahn R; Hamm CW; Schneider S; Zeymer U; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Sabin G; Senges J;
    Am J Cardiol; 2005 Jun; 95(11):1302-8. PubMed ID: 15904633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention.
    Chu WW; Rha SW; Kuchulakanti PK; Cheneau E; Torguson R; Pinnow E; Alexieva-Fournadjiev J; Pichard AD; Satler LF; Kent KM; Lindsay J; Waksman R
    Am J Cardiol; 2006 Jan; 97(1):34-7. PubMed ID: 16377280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.